ABVC Stock Analysis: Buy, Sell, or Hold?
ABVC - ABVC BioPharma, Inc. Common Stock
$1.93
-0.09 (-4.47%)
▼
5d:
-6.78%
30d:
-9.4%
90d:
-31.57%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Get Alerted When ABVC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABVC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABVC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABVC is currently trading at $1.93, which is considered oversold relative to its 30-day fair value range of $2.02 to $2.26.
Technical Outlook: Technically, ABVC is in a strong downtrend. The price is currently testing key support at $1.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABVC is in a strong downtrend. The price is currently testing key support at $1.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.02 -
$2.26
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- NEUTRAL: Near Wall St target ($2.02)
- CAUTION: Recommendation downgraded due to -6.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.02 -
$2.26
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.37
(19.0%)
Support & Resistance Levels
Support Level
$1.94
Resistance Level
$2.20
Current Trend
Strong Downtrend
Fundamental Context
Wall Street Target
$2.02
Revenue Growth (YoY)
104.5%
Last updated: February 02, 2026 10:57 AM ET
Data refreshes hourly during market hours. Next update: 11:57 AM
Data refreshes hourly during market hours. Next update: 11:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABVC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
